Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

3.84
+0.01000.26%
Post-market: 3.83-0.0086-0.22%19:30 EDT
Volume:856.38K
Turnover:3.28M
Market Cap:292.98M
PE:-3.17
High:3.86
Open:3.84
Low:3.78
Close:3.83
52wk High:15.74
52wk Low:2.83
Shares:76.30M
Float Shares:63.49M
Volume Ratio:0.27
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2104
EPS(LYR):-1.1819
ROE:-32.38%
ROA:-19.59%
PB:0.94
PE(LYR):-3.25

Loading ...

Fulcrum Therapeutics price target raised to $8 from $7 at BofA

TIPRANKS
·
May 10

Bank of America Securities Keeps Their Sell Rating on Fulcrum Therapeutics (FULC)

TIPRANKS
·
May 10

Fulcrum Therapeutics grants 55,500 inducement stock options at $7.02 per share

Reuters
·
May 09

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 09

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 09

Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom

Reuters
·
May 08

Fulcrum Therapeutics director Joshua Lehrer-Graiwer files initial beneficial ownership statement

Reuters
·
May 02

Fulcrum Therapeutics announces annual shareholder meeting

Reuters
·
May 01

Fulcrum Therapeutics Signals Strong Momentum in Earnings Call

TIPRANKS
·
Apr 28

Fulcrum Therapeutics posts corporate presentation on pociredir oral HbF inducer for sickle cell disease

Reuters
·
Apr 27

Fulcrum Therapeutics reports Q1 EPS (25c), consensus (30c)

TIPRANKS
·
Apr 27

Fulcrum Therapeutics CFO Alan Musso to retire

TIPRANKS
·
Apr 27

Fulcrum Therapeutics Highlights Q1 Results and Sickle Cell Progress

TIPRANKS
·
Apr 27

Fulcrum Therapeutics Inc - on April 23, Terminated License Agreement Dated July 5, 2023 With Camp4 - SEC Filing

THOMSON REUTERS
·
Apr 27

Fulcrum Q1 FY26 net loss widens to $18.9 million; cash drops to $333.3 million

Reuters
·
Apr 27

Fulcrum Therapeutics Q1 EPS $(0.25) Beats $(0.30) Estimate, Ended The First Quarter Of 2026 With $333.3M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into 2029

Benzinga Earnings
·
Apr 27

BRIEF-Fulcrum Therapeutics Q1 Basic EPS USD -0.25

Reuters
·
Apr 27

Fulcrum Therapeutics Inc - CFO Alan Musso Plans to Retire Later This Year

THOMSON REUTERS
·
Apr 27

Fulcrum Therapeutics Q1 Operating Income USD -22.186 Million VS. Ibes Estimate USD -23 Million

THOMSON REUTERS
·
Apr 27

Fulcrum Therapeutics Q1 Net Income USD -18.891 Million

THOMSON REUTERS
·
Apr 27